The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Osimertinib Then Chemotherapy in EGFR-mutated Lung Cancer With Osimertinib Third-line Rechallenge
Official Title: Osimertinib Then Chemotherapy in EGFR-mutated Lung Cancer With Osimertinib Third-line Rechallenge
Study ID: NCT04335292
Brief Summary: This phase II single-armed study will examine the clinical utility of retreating patients with osimertinib, in the third-line, following first-line treatment with osimertinib and second-line treatment with platinum and pemetrexed chemotherapy. The current standard of care for first-line Epidermal Growth Factor Receptor (EGFR) mutated Advanced Non-Small Cell Lung Cancer (aNSCLC) is osimertinib, followed by cytotoxic chemotherapy. The repeat of osimertinib following previous treatment failure is investigational, although supported by scientific rationale. The dosing and scheduling of osimertinib follows its use in approved settings. The investigators examine its tolerability and efficacy in this setting to ensure osimertinib is a safe third-line option for patients with Epidermal Growth Factor Receptor mutated (EGFR+) Advanced Non-Small Cell Lung Cancer(aNSCLC).
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
BC Cancer Agency, Vancouver, British Columbia, Canada
Lions Gate Hospital, Vancouver, British Columbia, Canada
William Osler Health System, Brampton, Ontario, Canada
Hamilton Health Sciences Centre, Juravinski Cancer Centre, Hamilton, Ontario, Canada
Grand River Regional Cancer Centre, Kitchener, Ontario, Canada
London Regional Cancer Program of the Lawson Health Research Institute, London, Ontario, Canada
Durham Regional Cancer Centre, Lakeridge Health, Oshawa, Ontario, Canada
The Ottawa Hospital, Ottawa, Ontario, Canada
Sunnybrook Research Institute, Toronto, Ontario, Canada
Princess Margaret Hospital, Toronto, Ontario, Canada
Name: Mark Vincent, MD
Affiliation: Lawson Health Research Institute
Role: PRINCIPAL_INVESTIGATOR